Projects per year
Personal profile
Biography
Simon Lewis is a Neurologist who has sub-specialised in degenerative diseases of the brain including Parkinson’s Disease, Dementia with Lewy Bodies and related conditions. He works as a Clinical Academic seeing patients and conducting research to improve our understanding and treatment of these brain disorders.
His research program is intentionally broad but highly integrated and directed towards improving the lives of people living with neurodegenerative brain diseases. He has previously utilised a range of novel techniques including neuroimaging (brain scanning), neurophysiology (e.g. recording brain waves), neuropathology (leads the NSW Movement Disorders Brain Donor Program), chronobiology (e.g. measuring melatonin), neurogenetics and other peripheral biomarkers from blood tests.
These approaches have been used to evaluate a variety of symptoms including dementia, gait disturbance, sleep-wake problems and hallucinations. Some of these approaches are targeting patients who are troubled by specific symptoms, whereas other work is focused on predicting who will develop degenerative diseases at the earliest possible point in time so as to increase our chances of preventing, slowing or curing these conditions. To this end, he is currently conducting a series of disease modifying drug trials in patients who have been diagnosed with degenerative brain disease. Furthermore, he also trains and mentors junior doctors, nurses and a range of research students. He invests in this capacity building to train the next generation of clinicians and researchers.
His research has attracted significant funding from a range of sources including the National Health and Medical Research Council (NHMRC), the Australian Research Council (ARC) and the international Michael J Fox Foundation. Send him a message, if you’d like to learn more about his work.
External positions
Chair of the International Consortium for Freezing of Gait
2024 → …
Clinical Lead for the Australian Parkinson's Mission
2019 → …
Fingerprint
- 1 Similar Profiles
-
SEL003: A Phase 2 Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probable Progressive Supranuclear Palsy
O'Brian, T., Lewis, S., West, S. & Harvey, C.
15/08/24 → 13/03/29
Project: Research
-
TEMPO-4: 58-week Open-label Trial of Tavapadon in Parkinson’s Disease (TEMPO-4 Trial)
Lewis, S., West, S. & Harvey, C.
8/08/24 → 3/04/29
Project: Research
-
TEMPO-2: A phase 3, double-blind, randomized, placebo-controlled, parallel-group, flexible-dose, 27 week trial to evaluate the efficacy, safety, and tolerability of Tavapadon in early Parkinson's Disease (TEMPO-2 trial)
Lewis, S., West, S. & Harvey, C.
7/08/24 → 3/04/29
Project: Research
-
A Phase 2a, Multi Centre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Effect of 12 Weeks Treatment with Oral PXS-4728A on Microglia Activation, as Measured by Positron Emission Tomography, in Participants with Isolated Rapid Eye Movement Sleep Behavior Disorder
Lewis, S., West, S. & Harvey, C.
31/07/24 → 12/06/29
Project: Research
-
APM002: A Randomised, Double-Blind, Placebo-Controlled, 60 Week, Phase II Clinical Trial of Ambroxol and Doxycycline in Moderate Severity Parkinsons Disease
Cooper, A. A., Lewis, S., West, S. & Harvey, C.
25/07/24 → 6/05/29
Project: Research
-
A Call for Change: updating the operational definition for dementia in Parkinson's disease
Kulisevsky, J., Litvan, I., Weintraub, D., Goldman, J. G., Tröster, A. I. & International Parkinson and Movement Disorder Society PD-MCI Study Group, Mar 2025, In: Movement Disorders Clinical Practice. 12, 3, p. 296-301 6 p.Research output: Contribution to journal › Article › peer-review
-
An audit on the assessment and management of osteoporosis in a Parkinson's and related diseases clinic in Australia
Amarasekera, N. N., Taylor, J., Coppin, C. & Lewis, S. J. G., 15 Jan 2025, In: Journal of Neurology. 272, 2, p. 1-7 7 p., 139.Research output: Contribution to journal › Article › peer-review
Open AccessFile6 Downloads (Pure) -
Blarcamesine for the treatment of Early Alzheimer's Disease: results from the ANAVEX2-73-AD-004 Phase IIB/III trial
Macfarlane, S., Grimmer, T., Teo, K., O'Brien, T. J., Woodward, M., Grunfeld, J., Mander, A., Brodtmann, A., Brew, B. J., Morris, P., Short, C., Kurrle, S., Lai, R., Bharadwaj, S., Drysdale, P., Sturm, J., Lewis, S. J. G., Barton, D., Kalafatis, C., Sharif, S., & 40 others , 1 Jan 2025, In: The Journal of Prevention of Alzheimer's Disease. 12, 1, p. 1-12 12 p., 100016.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)12 Downloads (Pure) -
Could adaptive deep brain stimulation treat freezing of gait in Parkinson’s disease?
Klocke, P., Loeffler, M. A., Lewis, S. J. G., Gharabaghi, A. & Weiss, D., Apr 2025, In: Journal of Neurology. 272, 4, p. 1-13 13 p., 267.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)10 Downloads (Pure) -
Dysregulation of monounsaturated fatty acids is related to α-synuclein in multiple system atrophy
Isik, F. I., Fu, Y. H., Pickford, R., Cheng, Q., Yang, Y., Lewis, S. J. G., Dzamko, N., Halliday, G. M. & Kim, W. S., 23 May 2025, (E-pub ahead of print) In: Movement Disorders. 11 p.Research output: Contribution to journal › Article › peer-review
Open Access